2500名心力衰竭患者的表征及其最佳医疗治疗的分析:来自AMERICCAASS注册表的见解
Alex David Sotomayor-Julio1,2,3, Sebastián Seni-Molina2, Juliana María Gutiérrez-Posso2
1Servicio de Cardiología, Fundación Valle del Lili, Cali, Colombia.
Global heart
|March 17, 2025
概括
这项研究表明,美洲心力衰竭 (HF) 患者的个人资料与全球数据一致,但最佳医疗治疗 (OMT) 坚持程度较低. 需要有针对性的战略来改善该地区的治疗和患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 临床研究 临床研究
背景情况:
- 心力衰竭 (HF) 是全球主要的健康问题,导致大量住院治疗和死亡率.
- 现有的高频研究主要来自发达国家,为拉丁美洲和加勒比地区等地区创造知识差距.
- 优化医疗疗 (OMT) 对于改善HF患者的治疗结果至关重要.
研究的目的:
- 确定美洲心力衰竭患者的社会人口统计和临床特征.
- 评估这些患者对最佳医疗治疗 (OMT) 的坚持.
- 为了确定美洲内HF护理的潜在差异.
主要方法:
- 美国CASS注册表是一项前性,观察性,多中心研究.
- 收集了2500名被诊断患有HF的成年患者的数据,包括住院和门诊患者.
- 评估了社会人口统计学,临床数据和基于左心室喷射率 (LVEF) 的OMT的坚持.
主要成果:
- 该研究包括2500名HF患者;36%住院,64%门诊,平均年龄为66岁.
- 大多数患者患有HF,左心室喷射分数减少 (LVEF ≤40%).
- 四倍治疗的坚持率很低:减少LVEF的21%,轻度减少LVEF的12.3%.
结论:
- 美洲HF患者的社会人口统计和临床概况与国际调查结果相似.
- 这一群人对OMT的遵守率较低,凸显了指导方针实施中的重大差距.
- 需要制定特定区域的战略,以提高药物治疗的坚持性和改善HF患者的治疗结果.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.4K
07:09A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
1.5K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: β-Blockers
300
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
300
01:22Heart Failure Drugs: Diuretics
313
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
313
01:26Heart Failure Drugs: Inotropic Agents
481
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
481